Editorial Commentary
Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma
Abstract
The term ‘’Non-clear cell Renal Cell Carcinoma (nccRCC)’’ recognized a large series of renal tumours characterized of a specific genomic and morphological signature. Compared to clear cell renal cell carcinoma (ccRCC), these tumours are uncommon diagnoses with an overall incidence around 20–25% of primary kidney tumours) (1).
